TCM
ADPT icon

Tuttle Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Tuttle Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-27,973
Closed -$1.35M – 126
2020
Q2 		$1.35M Buy
+27,973
New +$1.02M 0.96% 32
2020
Q1 		– Sell
-42,558
Closed -$1.27M – 71
2019
Q4 		$1.27M Buy
+42,558
New +$1.22M 0.48% 51

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

Tuttle Capital Management's ADPT Position: Q3 2020 in Review

Tuttle Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q3 2020, closing a stake of 27,973 shares — an estimated $1.35M sold.

Tuttle Capital Management first reported a position in ADPT in Q4 2019 and held it in 2 quarters. The position peaked at $1.35M in Q2 2020. 206 funds tracked by Wall St. Rank hold ADPT as of Q3 2020.

  • Tuttle Capital Management reported no remaining Adaptive Biotechnologies position as of Q3 2020 after selling out during the quarter.
  • Tuttle Capital Management sold 27,973 Adaptive Biotechnologies shares in Q3 2020, an estimated $1.35M.
  • Tuttle Capital Management first reported a position in Adaptive Biotechnologies in Q4 2019 and held it in 2 quarters.
  • Tuttle Capital Management's Adaptive Biotechnologies position peaked at $1.35M in Q2 2020.
  • 206 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2020.

Based on Tuttle Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.